RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 1

Registered title, quoted from ClinicalTrials.gov

HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06515314, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7

    Inclusion criterion 6

    Another primary malignancy within 5 years (with some exceptions for completely-resected early-stage tumors)

    Exclusion criterion 2

  3. Subjects with potential fertility must agree to use effective contraceptive methods during the whole trials period and at least 1 year after receiving HRYZ-T102 cell transfusion treatment. HCG test for female with potential fertility must be negative within 7 days before apheresis.

    Inclusion criterion 11

    Toxicity of previous treatment has not been mitigated or ≤ Grade 1 at screening.

    Exclusion criterion 1

  4. ECOG performance status ≤1.

    Inclusion criterion 7

  5. Patients must have at least one measurable lesion defined by RECIST 1.1.

    Inclusion criterion 9

  6. Known HIV or syphilis infection, and/or active hepatitis C virus infection.

    Exclusion criterion 12

    HBV infect subjects with HBV-DNA≥2000IU/ml

    Exclusion criterion 13

  7. Pregnant or lactating female, or those whose HCG test is positive before enrollment.

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06515314, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • The patient must be willing to sign the informed consent form.
  • Age ≥18 years and ≤75 years.
  • HLA-A 02:03 allele positive
  • Histologically-confirmed AFP positive hepatocellular carcinoma (HCC) or other solid tumor, No benefits from curative surgery or other local therapies are expected ,at least one prior line of systematic treatment at screening, judged by investigators.
  • Fresh samples or formalin-fixed paraffin-embedded (FFPE) samples, immunohistochemistry (IHC)-stained AFP positive or serum AFP ≥400ng/ml.
  • Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7
  • ECOG performance status ≤1.
  • Estimated life expectancy ≥4 months.
  • Patients must have at least one measurable lesion defined by RECIST 1.1.
  • Patients with any organ dysfunction as defined below:

Leukocytes≥3.0 x 10\^9/L; blood platelets ≥75 x 10\^9/L; hemoglobin≥85g/L; Absolute lymphocyte count≥0.8 x 10\^9/L Serum albumin ≥ 30g/L; total bilirubin≤3×ULN; ALT/AST≤3×ULN ; Creatinine clearance ≥50mL/min; or serum creatinine ≤1.5×ULN; INR≤1.5×ULN; APTT≤1.5×ULN; LVEF≥50%; SpO2≥92%.

  • Subjects with potential fertility must agree to use effective contraceptive methods during the whole trials period and at least 1 year after receiving HRYZ-T102 cell transfusion treatment. HCG test for female with potential fertility must be negative within 7 days before apheresis.

Exclusion Criteria:

  • Toxicity of previous treatment has not been mitigated or ≤ Grade 1 at screening.
  • Another primary malignancy within 5 years (with some exceptions for completely-resected early-stage tumors)
  • With severe cardiovascular disease or presence of clinically-relevant central nervous system (CNS) disorders in six months before screening.
  • Systematic autoimmune disorders requiring long-term systematic immunosuppression
  • Have a history of hypersensitivity to cyclophosphamide or fludarabine, and it is known that any ingredient used in the treatment of this study will produce allergic reactions.
  • Current presence of or previously with hepatic encephalopathy
  • Organ transplanters and allogeneic cell transplanters.
  • Have a history of gastrointestinal bleeding or a definite tendency to gastrointestinal bleeding within 3 months before screening
  • Hereditary or acquired bleeding (e.g. coagulation dysfunction) or a tendency to clot
  • Subject has active infection or unexplained fever during screening and prior to cell transfusion
  • Have central nervous system metastasis with symptoms
  • Known HIV or syphilis infection, and/or active hepatitis C virus infection.
  • HBV infect subjects with HBV-DNA≥2000IU/ml
  • Pregnant or lactating female, or those whose HCG test is positive before enrollment.
  • Known uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure

Quoted from ClinicalTrials.gov, NCT06515314, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06515314, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06515314